Evidence map›Paper›PMID 37514128›Full record

ArticlePharmaceutics2023

Coleon U, Isolated from

Sofija Jovanović Stojanov, Epole N Ntungwe, Jelena Dinić, Ana Podolski-Renić, Milica Pajović, Patrícia Rijo, Milica Pešić

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Virtual screening, molecular dynamics simulations, andFrontiers in veterinary science · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sofija Jovanović StojanovInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0003-4348-6453
Epole N NtungweCBIOS (Research Center for Biosciences and Health Technologies), Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, 1749-024 Lisbon, Portugal.
Jelena DinićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0003-3371-2381
Ana Podolski-RenićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0001-7412-3685
Milica PajovićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0001-7312-0861
Patrícia RijoCBIOS (Research Center for Biosciences and Health Technologies), Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, 1749-024 Lisbon, Portugal.ORCID 0000-0001-7992-8343
Milica PešićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0002-9045-8239
University of Belgrade · RSUniversidade Lusófona · PTUniversity of Coimbra · PT

Funding

MINISTRY OF SCIENCE, TECHNOLOGICAL DEVELOPMENT AND INNOVATION OF THE REPUBLIC OF SERBIA 451-03-47/2023-01/ 200007
6 · The paper itself

Abstract

Multidrug resistance in cancer is often mediated by P-glycoprotein. Natural compounds have been suggested as a fourth generation of P-glycoprotein inhibitors. Coleon U, isolated from

Indexed as

cancer multidrug resistanceColeon UP-glycoprotein

Identifiers

PMID37514128
PMCPMC10385270
OpenAlexW4384203035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.